Cargando…
Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Medizin
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344950/ https://www.ncbi.nlm.nih.gov/pubmed/28084541 http://dx.doi.org/10.1007/s00393-016-0256-2 |
| _version_ | 1782513619998605312 |
|---|---|
| author | Gissel, C. Götz, G. Repp, H. |
| author_facet | Gissel, C. Götz, G. Repp, H. |
| author_sort | Gissel, C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5344950 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Springer Medizin |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-53449502017-03-21 Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis Gissel, C. Götz, G. Repp, H. Z Rheumatol Leserbrief Springer Medizin 2017-01-13 2017 /pmc/articles/PMC5344950/ /pubmed/28084541 http://dx.doi.org/10.1007/s00393-016-0256-2 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| spellingShingle | Leserbrief Gissel, C. Götz, G. Repp, H. Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis |
| title | Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis |
| title_full | Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis |
| title_fullStr | Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis |
| title_full_unstemmed | Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis |
| title_short | Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis |
| title_sort | reply to: need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis |
| topic | Leserbrief |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344950/ https://www.ncbi.nlm.nih.gov/pubmed/28084541 http://dx.doi.org/10.1007/s00393-016-0256-2 |
| work_keys_str_mv | AT gisselc replytoneedforimprovementsinreportedcosteffectivenessofadalimumabinrheumatoidarthritis AT gotzg replytoneedforimprovementsinreportedcosteffectivenessofadalimumabinrheumatoidarthritis AT repph replytoneedforimprovementsinreportedcosteffectivenessofadalimumabinrheumatoidarthritis |